Optimization of Protein Entrapment in Affinity Microcolumns using Hydrazide-Activated Silica and Glycogen as a Capping Agent by Vargas-Badilla, John et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
David Hage Publications Published Research - Department of Chemistry 
7-15-2019 
Optimization of Protein Entrapment in Affinity Microcolumns 






David S. Hage 
Follow this and additional works at: https://digitalcommons.unl.edu/chemistryhage 
 Part of the Medicinal-Pharmaceutical Chemistry Commons 
This Article is brought to you for free and open access by the Published Research - Department of Chemistry at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in David Hage Publications 
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Optimization of Protein Entrapment in Affinity Microcolumns 
using Hydrazide-Activated Silica and Glycogen as a Capping 
Agent
John Vargas-Badilla, Saumen Poddar, Shiden Azaria, Chenhua Zhang, and David S. Hage*
Chemistry Department, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
Abstract
Several approaches were compared for the entrapment of proteins within hydrazide-activated silica 
for use in affinity microcolumns and high performance affinity chromatography. Human serum 
albumin (HSA) and concanavalin A (Con A) were used as model proteins for this work. Items 
considered in this study included the role played by the solution volume, amount of added protein, 
and use of slurry vs. on-column entrapment on the levels of solute retention and extent of protein 
immobilization that could be obtained by means of entrapment. The levels of retention and protein 
immobilization were evaluated by injecting warfarin or 4-methylumbellipheryl α-D-
mannopyranoside as solutes with known binding properties for HSA or Con A. Altering both the 
solution volume and amount of added protein led to an increase of up to 17-fold in the extent of 
protein immobilization for HSA in slurry-based entrapment; on-column entrapment provided an 
additional 3.6-fold increase in protein content vs. the optimized slurry method. Similar general 
trends were seen for Con A. The protein contents obtained by entrapment for HSA or Con A (i.e., 
up to ~87 and 46 mg/g silica, respectively) were comparable to or higher than levels reported for 
the covalent immobilization of these proteins onto silica. The retention of warfarin on the 
entrapped HSA was at least 1.7-fold higher than has been obtained under comparable support and 
mobile phase conditions when using covalent immobilization. These results indicated that 
entrapment can be an attractive alternative to covalent immobilization for proteins such as HSA 
and Con A, with this approach serving as a potential means for obtaining good solute binding and 
retention in work with affinity microcolumns or related microscale devices.
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High performance affinity chromatography (HPAC) is a method in which an immobilized 
biological agent, or affinity ligand, is placed onto an HPLC support (e.g., porous silica) and 
used as a selective binding agent for sample components [1,2]. The combination of such a 
support with the specificity and strong binding of many affinity ligands makes it possible 
with HPAC to quickly isolate, measure, or study specific targets even when they are present 
in complex biological samples. Other advantages of HPAC are its ability to be automated, to 
study biological interactions, and to reuse the same biological agent for many samples or 
binding studies [1–10].
The affinity ligand in HPAC is often covalently attached to the support through functional 
sites such as amines, carboxylates or sulfhydryl groups [2,11,12]. However, covalent 
coupling methods often have some multisite attachment, improper orientation or 
immobilization near a binding site, which can decrease the actual or apparent activity of the 
affinity ligand [2,12]. An alternative approach for immobilization is to use entrapment or 
encapsulation of the affinity ligand [12–16]. The encapsulation of various binding agents 
within sol-gels has been used for some time [12–15]. However, the sol-gels that result from 
traditional entrapment methods are generally not suitable for HPAC because of their band-
broadening and inability to be used at the pressures or flow rates that are often encountered 
in HPLC systems [12,16].
These limitations have been overcome in recent work with HPLC-based silica and the 
entrapment method shown in Figure 1. In this technique, an affinity ligand such as a protein 
is mixed with hydrazide-activated silica and a mildly oxidized form of glycogen (molar 
mass, ~2.5 × 105 kDa), which is used as a large capping agent [16]. The hydrazide groups on 
the support will not react with the binding agent but will form a stable covalent bond with 
aldehyde groups on the oxidized glycogen. This process results in some of the affinity ligand 
being entrapped within the stagnant mobile phase of the support as the glycogen binds to the 
activated silica and blocks the affinity ligand from leaving the pores or the region near the 
support’s surface. The result is an immobilization process in which the affinity ligand is kept 
within the support and in a form that is fully soluble and highly activity [16]. Although 
previous work has examined the effects of factors such as pore size and glycogen or protein 
levels on entrapment [16–19], there is still a need to further characterize items that influence 
the amount of protein that can be immobilized by this approach. This issue is of particular 
interest in work with affinity microcolumns (i.e., columns containing biological binding 
agents and with volumes in the low-to-mid μL range) [20], where a high protein content is 
frequently desirable for strong analyte binding and good retention [20–23].
This report will examine the effects of factors such as solution volume, relative protein 
amounts, and slurry versus on-column entrapment on the amount of protein and levels of 
solute retention that can be obtained with entrapment. Two model proteins will be used for 
this work: human serum albumin (HSA) and concanavalin A (Con A) [10,11]. These 
proteins are of general interest as binding agents in affinity columns for many drugs (i.e., the 
use of HSA in drug binding studies or chiral separations) or carbohydrate-containing agents 
(e.g., the use of Con A to bind glycopeptides) [6,7,9–11,21–26]. The retention properties 
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and level of entrapment of these proteins will be evaluated by using zonal elution studies and 
injected probe compounds with well-characterized binding to these agents. The results that 
are obtained under various conditions of entrapment will be used to identify conditions that 
maximize the protein content and solute retention of such supports. The protein content and 
retention behavior will be compared to prior covalent methods that have been employed with 
HSA and Con A. The results should provide valuable guidelines for future applications of 
entrapment with these and other proteins when using affinity microcolumns and related 
microscale systems [20–23,26].
2 Material and methods
2.1 Reagents
The HSA (essentially fatty acid free, ≥ 96% pure), Con A (type V, lyophilized powder, 
highly purified), glycogen (bovine liver type IX, total glucose ≥ 85 %, dry basis), racemic 
warfarin (purity ≥ 98%), 4-methylumbellipheryl α-D-mannopyranoside (MUM, purity ≥ 
96%) and 4-methylumbellipheryl α-D-galactopyranoside (MUGA, purity ≥ 98%) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Nucleosil Si-300 silica (7 μm particle 
diameter, 300 Å pore size) was obtained from Macherey Nagel (Duren, Germany). All other 
chemicals were of the purest grades available. Vivaspin 6 ultrafiltration tubes (30 kDa cutoff; 
Sartorius, Gottingen, Germany) were used for purification of the oxidized glycogen. All 
buffers and aqueous solutions were prepared using water from a Nanopure system 
(Barnstead, Dubuque, IA, USA). Buffers were filtered using 0.20 μm GNWP nylon 
membranes from Fisher Scientific (Pittsburgh, PA, USA) and were degassed by sonication 
under vacuum for at least 30 min prior to use.
2.2 Apparatus
The chromatographic system consisted of a 1200 isocratic pump from Agilent (Santa Clara, 
CA, USA), a Series 200 UV-Vis detector, and a vacuum degasser from Perkin-Elmer 
(Waltham, MA, USA). Samples were injected using a Rheodyne LabPro valve (Cotati, CA, 
USA) equipped with a 5 or 20 μL sample loop. An Isotemp 9100 circulating water bath 
(Fisher Scientific, Pittsburgh, PA, USA) and a water jacket from Alltech (Deerfield, IL, 
USA) were used for temperature control of the columns and mobile phases. The 
chromatographic data were collected and processed using LabView 8 software (National 
Instruments, Austin, TX, USA), and analyzed using PeakFit 4.12 (Systat Software, San Jose, 
CA, USA). Two PHD Ultra syringe pumps (Harvard Apparatus, Holliston, MA, USA) were 
used for the on-column entrapment method. An HPLC slurry packing system from 
ChromTech (Apple Valley, MN) was used for packing supports into the microcolumns.
2.3 Protein entrapment by the slurry method
The supports containing entrapped proteins were prepared from Nucleosil Si-300 silica that 
had first been converted into a diol-bonded form, as described previously [27]. This support 
has been found in prior work to be suitable for the entrapment of HSA and proteins with 
similar sizes to HSA [16–19]. The diol-bonded silica was later used in preparing hydrazide-
activated silica, with oxalic dihydrazide being employed as the activating agent [16,27].
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The initial conditions used for slurry-based entrapment were based on prior work with HSA 
and this method [16] (Note: modifications of this approach that were made and used later in 
this study are described in Section 3.1). These conditions involved making a slurry that 
contained 0.08 g of hydrazide-activated silica and 0.80 mL of a 10 mg/mL protein sample 
that were placed or prepared in a pH 5.0, 0.10 M potassium phosphate solution. This slurry 
was degassed for 10 min to remove any trapped air within the support. Next, 0.28 mL of a 
4.25 mg/ml solution of mildly oxidized glycogen in a pH 5.0, 0.10 M potassium phosphate 
solution was added to the mixture, giving a slurry that contained 15 mg glycogen/g silica. 
The glycogen had previously been oxidized in pH 5.0, 20 mM sodium acetate buffer that 
contained 15 mM sodium chloride, with 17 mg glycogen and 135 mg periodic acid being 
added to 4 mL of this buffer and allowed to react for 16 h in the dark; these conditions have 
been shown to oxidize about 0.5% of the glucose units in glycogen [16]. The oxidized 
glycogen was purified by ultrafiltration [19] and then used for entrapment.
The volume of the entrapment solution containing the hydrazide-activated support, protein 
and oxidized glycogen was adjusted to 2.0 mL by adding a pH 5.0, 0.10 M potassium 
phosphate solution. This slurry was mixed slowly for 16 h at 4°C. Finally, 50 μL of oxalic 
dihydrazide, which was present at a concentration of 1 mg/mL in a pH 5.0, 0.10 M 
potassium phosphate solution, was added and allowed to mix with the slurry for 1 h. This 
step was performed to cap any remaining aldehyde groups on the glycogen and to decrease 
possible non-specific binding that might occur later with such groups in the microcolumn. 
Control supports were prepared in the same manner, but with a pH 5.0, 0.10 M potassium 
phosphate solution being used in place of the protein solution during the entrapment step.
Several conditions were varied for the slurry-based entrapment method, with the goal of 
increasing the amount of entrapped protein and its retention of applied solutes. These 
conditions, as discussed in Section 3, included the solution volume and the total amount of 
protein that was used for entrapment. The supports prepared by slurry-based entrapment, or 
the activated supports used for on-column entrapment, and the corresponding control 
supports were suspended in pH 7.4, 0.067 M potassium phosphate buffer and downward 
slurry packed into 1.0 cm × 2.1 mm i.d. stainless steel microcolumns for evaluation and use 
in chromatographic studies. The packing solution for all supports was pH 7.4, 0.067 M 
potassium phosphate buffer and the packing pressure was 4000 psi (27.6 MPa). After 
packing, the microcolumns were placed in an HPLC system, where a pH 7.4, 0.067 M 
potassium phosphate buffer (for the HSA supports) [16,21–23] or a pH 5.0, 0.50 M sodium 
acetate that contained 1.0 mM calcium chloride and 1.0 mM manganese chloride (for the 
Con A supports) [16,28,29] was passed through each microcolumn at 0.5 mL/min for at least 
1 h or until a stable baseline was achieved. The microcolumns were stored in the same pH 
7.4 or 5.0 buffers and at 4°C when not in use.
2.4 Protein entrapment by an on-column method
An alternative approach to slurry entrapment that was considered for immobilization was 
on-column entrapment [17]. The hydrazide-activated support was prepared from the same 
type of silica and using the same general reaction conditions as described in the previous 
section for slurry-based entrapment [16,27]. This support was packed into 1.0 cm × 2.1 mm 
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i.d. stainless steel microcolumns at 4000 psi using pH 7.4, 0.067 M potassium phosphate 
buffer, as described in Section 2.3.
The microcolumns containing hydrazide-activated silica were next used with a dual syringe 
on-column entrapment procedure, as illustrated in Figure 2. In this method, each 
microcolumn containing a hydrazide-activated support was connected to two pumps that 
were each equipped with 250 or 500 μL syringes. These pumps were synchronized to pass a 
given solution through a microcolumn, with one syringe infusing the solution while the other 
was used to withdraw the solution at the same flow rate. The total solution volume in the 
syringes was 350–400 μL, and syringes were used to infuse or withdraw 75 μL of this 
solution (in the majority of studies) or 200 μL (in later work with 100 mg/mL HSA) during 
each cycle at a flow rate of 20 μL/min. A stop time of 1 min was included in this program 
between each change in direction for syringe movement to allow the solution to completely 
go through the microcolumn and to relieve any pressure buildup that had occurred before a 
change was made in the direction of solution application.
The on-column entrapment method was used with several microcolumns and with HSA 
concentrations that ranged from 12.5 to 100 mg/mL and Con A concentrations that ranged 
from 1.0 to 10 mg/mL. These solutions were each entrapped at room temperature. The on-
line entrapment procedure first involved applying for 4 h to the microcolumn a 350–400 μL 
solution that contained only the desired protein (e.g., HSA) in a pH 5.0, 0.10 M potassium 
phosphate solution. This step was followed by applying 400 μL of a mixture of the same 
protein plus 4.25 mg/mL of oxidized glycogen for 16 h. Finally, 350–400 μL of a 1 mg/mL 
oxalic dihydrazide solution that was prepared in a pH 5.0, 0.10 M potassium phosphate 
solution was passed through the microcolumn for 2 h. A control microcolumn was prepared 
under the same conditions, with the exception of using only a pH 5.0, 0.10 M potassium 
phosphate solution in place of the protein solution. Immediately after the entrapment 
procedure was completed, the microcolumn was connected to an HPLC pump and washed at 
0.50 mL/min for 1 h with either pH 7.4, 0.067 M potassium phosphate buffer (for the HSA 
microcolumns) or pH 5.0, 0.50 M sodium acetate that contained 1.0 mM calcium chloride 
and 1.0 mM manganese chloride (for the Con A microcolumns) to wash away any excess 
reactants (e.g., unreacted oxidized glycogen or oxalic dihydrazide, and any remaining, non-
entrapped protein). The microcolumns were stored in the same pH 7.4 or 5.0 buffers at 4°C 
when not in use.
2.5 Chromatographic studies
The mobile phase that was used in the chromatographic studies with the entrapped HSA 
microcolumns was pH 7.4, 0.067 M potassium phosphate buffer [16,21–23]. The mobile 
phase for the entrapped Con A microcolumns was pH 5.0, 0.50 M sodium acetate that 
contained 1.0 mM calcium chloride and 1.0 mM manganese chloride [28,29]. All 
microcolumns were equilibrated with their corresponding buffer at 0.50 mL/min for at least 
1 h before any sample injections were made onto the column. During these experiments, the 
temperature was maintained at 37 °C for the HSA microcolumns and at 20 °C for the Con A 
microcolumns, as well as for their respective control microcolumns.
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The probes that were injected onto these microcolumns to measure their retention and to 
estimate their protein content were racemic warfarin for HSA and MUM for Con A. The 
wavelengths used for detection were 308 nm for warfarin, 316 nm for MUM or MUGA, and 
205 or 220 nm for sodium nitrate, with sodium nitrate and MUGA being used as non-
retained solutes and markers for the void time of the system in work with HSA and Con A, 
respectively [16–19,28,29]. Sample solutions containing these probes were prepared in the 
same mobile phase that was used for each corresponding microcolumn. The injection 
volume was 5 μL or 20 μL.The samples were injected at 0.50 mL/min and contained 10–20 
μM warfarin, 5–10 μM MUM or MUGA, and 2.5–5.0 μM sodium nitrate. No significant 
variations in the retention factors for the injected probes or non-retained solutes were seen 
over this range of sample concentrations, indicating that linear elution conditions were 
present. The retention factors also showed no variation with small changes in the flow rate, 
in agreement with previous observations made for warfarin and related solutes in prior 
studies with columns containing covalently immobilized HSA [9,21,30].
The retention time for each injected solute was estimated by analyzing the chromatograms 
with PeakFit 4.12. These peaks were processed by using the exponentially-modified 
Gaussian and half-Gaussian modified Gaussian function of PeakFit, followed by 
determination of each peak’s first statistical moment. All of the retention factors were 
determined for data acquired over at least three injections of the probe compounds or non-
retained solutes on the protein microcolumns and control microcolumns. The extra-column 
void time of the system was found by measuring the elution time of sodium nitrate or 
MUGA when a zero-volume union was placed instead of a microcolumn into the 
chromatographic system [21].
3 Results and discussion
3.1 Optimization of slurry-based entrapment for HSA
The slurry-based method of entrapment is the original form of this immobilization approach 
[16] and is the format that has been used in most prior work with this technique [18,19]. 
This procedure uses a slurry that contains a mixture of hydrazide-activated silica, oxidized 
glycogen and the protein of interest for the entrapment process [16]. Previous studies have 
examined the effects of using different types of supports and pore sizes on the amount of 
protein that can be entrapped by this method [16,19]. The effects of varying the amount of 
oxidized glycogen vs. silica and the means for preparing the hydrazide-activated silica or 
oxidized glycogen have also been considered [16,19]. In addition, some preliminary work 
has examined the effect of varying the total amount of protein that is added to the 
entrapment mixture [16]. One factor that has not been examined in these prior studies is the 
way in which the final protein content of the support is altered when varying the total 
volume of solution that is used for slurry-based entrapment.
HSA was used as the test protein for this work because it has been employed as a model 
binding agent in numerous previous studies aimed at the creation or optimization of covalent 
immobilization methods [5,31–34]. In addition, HSA has been of ongoing interest in binding 
studies based on HPAC because this protein is a serum transport agent for many drugs and 
can act as a chiral stationary phase for a number of these solutes [5–10]. This protein, which 
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consists of a single polypeptide chain with a molar mass of 66.5 kDa [24], also has well-
characterized binding to the drug warfarin [5,16]. This last fact was used in this report by 
employing warfarin as a probe to estimate and compare, through retention factor 
measurements, the amounts of active HSA that were present in supports and microcolumns 
prepared by entrapment (Note: this approach, and related methods using warfarin as a probe, 
have been found in previous studies to give good agreement with direct measurements of 
entrapped HSA content based on protein assays) [16,18].
Table 1 shows the results that were obtained in this study when the total volume of the HSA/
glycogen solution and/or the total added amount of HSA were varied in this entrapment 
method. Some adjustments in the amounts of silica and oxidized glycogen that were added 
to this mixture were also made during this process to provide consistent relative amounts for 
these agents. In going from Procedure 1 to 2 in Table 1, the solution volume was decreased 
by 70% from 1.0 to 0.30 mL. The masses of glycogen and silica were decreased to keep 
their ratio in the range of 15–18 mg glycogen/g silica. The added amount of HSA was also 
decreased slightly from that used in Procedure 1 (i.e., from 8.0 to 6.0 mg); this gave a 
mixture that contained a 20% increase in the relative amount of HSA vs. silica (i.e., 120 vs. 
100 mg HSA/g silica). Under these conditions, the final protein content, as calculated from 
the measured retention of warfarin [16,18,31], gave a 1.4-fold apparent increase from 1.9 to 
2.6 mg HSA/g silica; however, this change was not significant at the 95% confidence level. 
A further reduction in the solution volume to 0.20 mL, as made in Procedure 3 and with no 
change in the amount of added HSA from Procedure 1 (8.0 mg), provided an increase in the 
entrapped protein content of 3.2-fold from the initial conditions. This difference was 
significant at the 95% confidence level and indicated that a decrease in solution volume 
could alter and be used to increase the final protein content of a support that was made by 
slurry-based entrapment.
The effect of altering the total amount of protein, with a small change in the solution 
volume, in the entrapment procedure was next considered. This is demonstrated in going 
from the conditions in Procedure 1 to those Procedure 4, in which the amount of added HSA 
was increased from 8.0 to 25.2 mg and the solution volume was decreased slightly (28%) 
from 1.00 to 0.72 mL. To compensate for the decrease in solution volume, the masses of 
silica and glycogen were decreased to provide the same mass ratio between these agents as 
was present in Procedure 1. However, the relative amount of added HSA vs. silica was now 
increased by 4-fold. The combined effect of this increase in the relative amount of HSA and 
the modest decrease in solution volume was a 5.4-fold increase in the amount of entrapped 
HSA. This increase was significant at the 95% confidence level and indicated that an 
increase in the amount of added protein along with a decrease in solution volume could be 
used to provide a large increase in the level of protein immobilization during entrapment.
The results obtained with Procedure 2–4 were next used to identify a new set of conditions 
(i.e., Procedure 5) for examining the effect of significantly altering both the amount of added 
protein and the solution volume in the slurry entrapment method. This set of conditions used 
the same mass ratios of HSA vs. silica and glycogen vs. silica as were used in Procedure 4 
but now used a solution volume that was decreased 3.6-fold from 0.72 to 0.20 mL. This 
modification in the entrapment method also resulted in a large increase in the amount of 
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entrapped protein, now giving a final protein content of over 32 mg HSA/g silica. This 
amount was 3.2-fold higher than was seen in Procedure 4 and 17-fold higher than the protein 
content that was obtained with the initial conditions used in Procedure 1. Based on the 
increase that was noted in this last group of studies, the conditions employed in Procedure 5 
(i.e., in which the solution volume was minimized and the amount of added protein in this 
solution was maximized) were selected for further use in the slurry-based entrapment, with a 
modified version of this method being employed with HSA in Section 3.2 and with Con A in 
Section 3.3.
3.2 Optimization of on-column entrapment for HSA
An on-column format is another possible approach for protein entrapment [17]. In this 
method, proteins and other reagents are circulated through hydrazide-activated silica that has 
been packed into a column. The advantage of this approach is that the reaction mixture 
contains the support within a region that can now make use of the smallest possible volume 
for the entrapment process. This reduced volume promotes better contact of the applied 
protein with the pores or region near the surface of the support, which in turn should result 
in a larger amount of entrapped protein than the slurry-based method [17].
In this report the on-column entrapment system was initially compared to the slurry-based 
method for the entrapment of HSA. This work was carried out by using a slurry-based 
method that employed 100 mg/mL HSA as a reference, as based on conditions obtained 
from Table 1. The concentration of HSA was varied in the on-column method from 12.5 to 
100 mg/mL. The same concentration of oxidized glycogen that was present in the slurry-
based method was used in the on-column method (i.e., 4.25 mg/mL). In addition, the total 
volume for the HSA/glycogen solution was kept at 0.35–0.40 mL in both the slurry and on-
column methods. Although these solution volumes were slightly higher than the final value 
of 0.20 mL that was used for the slurry method in Procedure 5 of Table 1, this volume did 
make it possible to now make a direct comparison between the slurry-based and on-column 
entrapment methods under equivalent solution reaction conditions.
Table 2 summarizes the final protein contents of the supports that were prepared by the 
slurry and on-column methods. For the on-column method, a 1.8-fold increase in protein 
content was seen as the concentration of the applied HSA increased from 12.5 to 50 mg/mL, 
and a 3.2-fold increase was seen when going from 12.5 to 100 mg/mL HSA, with both of 
these increases being significant at the 95% confidence level. The results obtained when 
going from 25 to 100 mg/mL HSA in the on-column entrapment method gave protein 
contents that were 1.8-to 3.6-fold higher than was obtained when using slurry-based 
entrapment with 100 mg/mL HSA, with all of these differences being significant at the 95% 
confidence level. In addition, the protein content obtained when using only 12.5 mg/mL 
HSA for on-column entrapment was comparable and statistically equivalent to that obtained 
when using 100 mg/mL HSA in the slurry-based method. Finally, the highest protein content 
that was obtained here with on-column entrapment was over 46-fold larger than the protein 
content that was obtained with the initial conditions used in Procedure 1 of Table 1 for the 
slurry-based entrapment of HSA.
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The results in Table 2 clearly indicated that the on-column method allowed for more 
effective entrapment than the slurry method. This feature made it possible with the on-
column method to provide much higher levels of entrapment than the slurry method when 
using the same total amount of protein, as seen in Table 2 for these two approaches when 
both used 100 mg/mL HSA. This feature also made it possible to obtain comparable levels 
of entrapment at much lower levels of applied protein in on-column entrapment, as indicated 
in Table 2 by the on-column result at 12.5 mg/mL HSA vs. the slurry method result at 100 
mg/mL HSA. In the later situation, the slurry method used 40 mg HSA (i.e., a 0.40 mL 
portion of 100 mg/mL HSA) to prepare the HSA microcolumn, while the on-column method 
only needed 5 mg HSA (0.4 mL of 12.5 mg/mL HSA). This made the on-column method a 
more efficient and cost-effective approach for entrapment than the slurry method for the 
immobilization of HSA in affinity microcolumns.
Figure 3 shows some typical chromatograms that were obtained for HSA microcolumns that 
were prepared by the slurry-based and on-column procedures. This figure indicates that 
warfarin could easily access and be retained by the entrapped protein in these microcolumns. 
This observation agrees with prior work that has examined the retention of warfarin and 
other drugs with columns containing entrapped HSA or alpha1-acid glycoprotein (i.e., 
another serum transport protein) [16–19]. The chromatograms in Figure 3 also illustrate the 
ability of on-column entrapment to give higher retention than slurry-based entrapment when 
both methods use the same total amount of protein (i.e., see top and bottom chromatograms, 
in which both are based on the use of 100 mg/mL HSA for entrapment). In addition, Figure 
3 demonstrates how comparable or even higher amounts of retention can be obtained by on-
column entrapment when using less added amounts of protein than slurry-based entrapment. 
This last situation can be seen by comparing by the top chromatogram, which is for the 
slurry method at 100 mg/mL HSA, and the middle two chromatograms, which are for the 
on-column method when using 12.5 or 50 mg/mL HSA and which give equivalent or higher 
retention for warfarin than the slurry method.
Many previous studies have used HSA as a model protein to optimize and develop new 
immobilization methods for silica supports in HPAC. Examples of these other 
immobilization techniques have included the Schiff base method, the N-hydroxysuccinimide 
method, and various sulfhydryl-reactive techniques [31–34]. Use of these methods with the 
same type of silica as employed in this study have resulted in final protein contents that have 
ranged from 8–54 mg HSA/g silica [31–34]. These amounts are comparable to those 
obtained in this study when using on-column entrapment, with entrapment even reaching a 
level of almost 87 mg HSA/g silica (or 1.30 μmol/g silica) with the largest amount of HSA 
that was employed. The potential of entrapment to immobilize more protein than these 
covalent methods is linked to the use of a three-dimensional region (e.g., the pore volume) to 
contain the protein instead of using only the surface area of the support. This difference 
would be expected to provide entrapment with a larger level of immobilization particularly 
in cases where a protein is quite soluble and can be added to the entrapment solution at high 
concentrations, as is the case with HSA [24].
Another difference between the covalent and entrapment methods is that the entrapment 
process results in immobilized HSA that is present in an essentially fully active form 
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[16,18], while covalent immobilization methods have typically given activities of 7–87% for 
this same protein [31,32,34]. This difference means entrapment can not only be used to 
potentially produce a larger amount of immobilized protein but to also provide higher 
retention than a covalent method by providing a higher level of protein activity. For example, 
the specific retention factors reported for warfarin on HSA columns that have been prepared 
by various covalent methods have ranged from 7.6–80 [31,32,34]. In this study, specific 
retention factors for warfarin as high as almost 135 were obtained when using the same type 
of support and mobile phase/temperature conditions as used in the prior cited work with 
covalent immobilization schemes.
3.3 Optimization of entrapment for Con A
Con A was another protein that was used as a model to test and optimize the entrapment 
scheme that was employed in this report. This work was done to see if the trends observed 
for entrapment with HSA also applied to other binding agents. Con A was entrapped and 
used at pH 5.0, a condition at which this protein mainly exists as a dimer (molar mass of 53 
kDa, with each monomer having a mass of 26.5 kDa) [10,28,29]. Although the dimer of Con 
A has a slightly lower mass than HSA, the hydrodynamic radius of the Con A dimer is 
comparable to and slightly larger than that of HSA (i.e., 4.1 nm vs. 3.5 nm) [35,36]. 
Furthermore, Con A is similar to HSA in that it has well-described binding for some solutes, 
one of which is the fluorescent sugar MUM [28,29]. This last feature made it again possible 
to use retention measurements with MUM as a probe compound to estimate the content of 
active Con A in affinity microcolumns and within supports that were prepared under various 
entrapment conditions.
The results that were obtained for the entrapment of Con A are summarized in Table 3. The 
lower solubility of Con A compared to HSA [24,37,38] did limit the range of concentrations 
for Con A that could be used for the entrapment process (i.e., values up to 10 mg/mL). 
However, the general trends seen in Table 2 for HSA also appeared in the data for Con A in 
Table 3. For instance, an increase in the total amount of Con A that was used for on-column 
entrapment again resulted in an increase in the final level of entrapped protein; the amount 
of entrapped protein increased by 2.2-fold (i.e., a result significant at the 95% confidence 
level) when going from an applied concentration of 1.0 to 10 mg/mL Con A. This increase, 
which occurred over a 10-fold range in the applied concentration of Con A, was smaller than 
the 3.2-fold increase seen in Table 2 over an 8-fold change in the concentration of HSA that 
was used for entrapment. This difference may be due to the loss of some Con A before 
immobilization, as some cloudiness was noted to occur during the preparation of a 10 
mg/mL Con A solution, which was then filtered prior to its use in entrapment.
Another similarity in the results for Con A and HSA was in the ability of the on-column 
approach to give more effective entrapment than the slurry method. For Con A, the use of 
on-column entrapment and a 1.0 mg/mL Con A solution gave a statistically-equivalent level 
of entrapment (at the 95% confidence level) to the use of slurry-based entrapment with 10 
mg/mL Con A. In addition, use of 10 mg/mL Con A for both slurry entrapment and on-
column entrapment resulted in a 2.6-fold higher amount of immobilized Con A for the on-
column method. The effect of these different levels of entrapment on the retention of MUM 
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is illustrated by the chromatograms in Figure 4. These chromatograms show how the use of 
only 1.0 mg/mL Con A in the on-column entrapment gave a support that was similar in 
retention behavior for MUM to that obtained with the slurry method when using 10 mg/mL 
Con A. This figure also shows how the use of 10 mg/mL Con A for on-column entrapment 
created a microcolumn that had higher retention for MUM than when using the same 
concentration of Con A in the slurry method.
These results were compared to those obtained in prior studies that have used a covalent 
immobilization method to couple Con A to silica. The highest Con A content that was 
obtained in this study (i.e., ~46 mg/g silica, or 0.86 μmol Con A dimer/g silica) was 
comparable to values of 40–50 mg Con A/g silica that have been reported for the Schiff base 
method of covalent immobilization [25,26]. This was the case even though the silica used in 
these earlier reports either had a lower [26] or larger surface area [25] than the support that 
was used for entrapment in this current work. These results indicated that entrapment could 
be used as a viable alternative to covalent immobilization methods for the preparation of 
Con A supports and columns. It was further noted that the levels of entrapment seen in Table 
3 for the slurry-based and on-column entrapment of Con A (i.e., 0.33 and 0.40–0.86 μmol 
dimer/g silica, respectively) were in the same general range as obtained in Table 2 when 
these entrapment methods were used with HSA (i.e., 0.36 and 0.41–1.30 μmol/g silica).
4 Conclusion
This report examined several factors that may influence the extent of entrapment for proteins 
such as HSA and Con A within HPLC-grade porous silica. Of particular interest was the use 
of entrapment to create affinity microcolumns [20]. The retention properties and levels of 
entrapment of the resulting microcolumns were evaluated by using injections of warfarin or 
MUM as probes for HSA and Con A, respectively [5,16,28,29]. It was found with HSA that 
altering both the solution volume and amount of added protein could lead to a significant 
increase in the extent of protein immobilization that was obtained in slurry-based 
entrapment. The amount of added protein was also found to be important when using on-
column entrapment with HSA, where a large increase in the final protein content of the 
supports was noted when comparing on-column and slurry-based entrapment. Similar results 
were obtained with Con A when comparing slurry-based vs. on-column entrapment.
The final, optimized conditions identified for the slurry entrapment of HSA gave a 17-fold 
higher protein content than conditions based on a previous approach for the entrapment of 
this protein (i.e., Procedure 1 in Table 1) [16]. The conditions that were optimized for the 
on-column entrapment of HSA gave over a 45-fold higher protein content than was obtained 
with the original procedure for slurry-based entrapment [16] and a 3.6-fold higher protein 
content than the optimized slurry method, when the latter approach used a comparable 
protein concentration and solution volume for the immobilization process. The largest 
protein content that was obtained for either the slurry-based or on-column entrapment of 
HSA (i.e., ~32 and 86 mg/g silica, respectively) was comparable to or larger than values of 
8–54 mg/g silica that have been reported for a number of covalent methods with the same 
type of silica as employed in this report [31–34]. In addition, the highest specific retention 
factor observed here for warfarin on an entrapped HSA microcolumn was 18-to 1.7-fold 
Vargas-Badilla et al. Page 11













higher than values that have been obtained when using covalent immobilization [31,32,34]. 
For Con A, the highest protein content that was measured in this study (i.e., ~46 mg/g silica) 
was in the same range as values that have been reported for covalent immobilization using 
other types of silica [25,26].
These results indicate that entrapment can be a valuable alternative to covalent 
immobilization for proteins such as HSA and Con A. These data also demonstrate how 
entrapment can provide higher levels of protein immobilization than covalent coupling 
techniques and result in supports and columns with increased levels of solute retention. 
These differences are believed to be due to two factors: the use of a three-dimensional region 
in entrapment instead of a surface for immobilization, and the loss of actual or apparent 
activity of the binding agent during covalent immobilization [16,18,31,32,34]. The trends 
noted in this study should provide valuable guidelines for future applications of HSA, Con A 
and other binding agents in HPAC. As illustrated in this report, the ability to prepare 
supports by entrapment should be especially attractive as a means to provide strong binding 
and good retention in future work with affinity microcolumns or related microscale devices 
that employ affinity ligands as immobilized agents [20–23,26,39].
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• Several procedures were evaluated for protein entrapment in hydrazide-silica.
• The protein content of each support was evaluated for use in affinity 
microcolumns.
• Human serum albumin and concanavalin A were used as model proteins.
• On-column entrapment was found to be more effective than a slurry-based 
method.
• The protein contents seen with entrapment met or exceeded those of covalent 
methods.
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Entrapment of a soluble protein using a hydrazide-activated support and mildly oxidized 
glycogen.
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Scheme for dual syringe method for on-column protein entrapment.
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Chromatograms obtained for racemic warfarin on columns that contained entrapped HSA, as 
prepared by slurry-based or on-column entrapment using various concentrations of HSA. 
Conditions: sample, 40 μM racemic warfarin, 5 μL; column size, 1.0 cm × 2.1 mm i.d.; flow 
rate, 0.50 mL/min; temperature, 37 °C. The total solution volume was 400 μL in the 
entrapment methods represented by the top three chromatograms and 350 μL in the 
procedure represented by the bottom chromatogram. Other conditions are provided in the 
Materials and methods. The dashed vertical line shows the mean elution time of sodium 
nitrate, which was used as a non-retained solute.
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Chromatograms obtained for MUM on columns that contained entrapped Con A, as 
prepared by slurry-based or on-column entrapment. Conditions: sample, 10 μM MUM, 5 μL; 
column size, 1.0 cm × 2.1 mm I.D.; flow rate, 0.50 mL/min; temperature, 20 °C. Other 
conditions are provided in the Materials and methods. The dashed vertical line shows the 
mean elution time of MUGA, which was used as a non-retained solute.
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Table 1.
Effect on protein content when varying reaction conditions for slurry-based entrapment of HSAa
Procedure
Entrapment conditions 1 2 3 4 5
Solution and support in entrapment mixture
 Total added solution volume (mL) 1.00 0.30 0.20 0.72 0.20
 Total added silica (mg) 80 50 50 63 50
HSA in entrapment mixture
 Conc. HSAC (mg/mL) 8.0 20 40 35 100
 Total Added HSA (mg) 8.0 6.0 8.0 25.2 20.0
 Added HSA vs. silica (mg/g) 100 120 160 400 400
Oxidized glycogen in entrapment mixture
 Cone, oxidized glycogen (mg/mL) 1.2 3.0 4.2 1.3 3.8
 Total added glycogen (mg) 1.2 0.90 0.84 0.94 0.75
 Added glycogen vs. silica (mg/g) 15 18 17 15 15
Properties of entrapped HSA supportb
 Specific retention factor, warfarin 3.0 (±0.6) 4.0 (±0.9) 9.5 (±2.6) 15.8 (±1.4) 49.9 (±7.9)
 Protein content (mg/g silica) 1.9(± 0.5) 2.6(± 0.8) 6.1(± 2.1) 10.2(± 2.2) 32.2(± 8.1)
e
Average retention factor for triplicate injections of racemic warfarin, where the numbers in parentheses represent a range of ± 1 S.D. For 
Procedure 5, the average retention factor was calculated from the results for two different batches of entrapped HSA supports.
b
The specific retention factors were measured at pH 7.4 and 0.5 mL/min at 37 °C and have been corrected for any binding by warfarin to the 
support in the absence of entrapped HSA. The protein content of each support was calculated from the specific retention factor for warfarin by 
using a molar mass for HSA of 66.5 kDa, the measured void volume of the column, the known packing density for the support (0.45 g/cm3) and an 
association equilibrium constant of 2.3 (± 0.4) × 105 M−1 for racemic warfarin with HSA at pH 7.4 and 37 °C [31].
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Table 2.













 100 mg/mL HSA
37.6 (± 5.2) 24.2 (±5.9) 0.36 (±0.09)
On-column method 12.5 mg/mL HSA 42.4 (±± 1.0) 27.3 (±5.4) 0.41 (±0.08)
On-column method 25 mg/mL HSA 68.2 (±3.8) 44.0 (±9.0) 0.66 (±0.14)
On-column method 50 mg/mL HSA 75.6 (±3.5) 48.7 (±9.9) 0.73 (±0.15)
On-column method 100 mg/mL HSA 134.5 (±5.3) 86.7 (±17.5) 1.30 (±0.26)
a
The numbers in parentheses represent a range of ± 1 S.D. for three sample injections. The specific retention factors were measured at pH 7.4 and 
0.5 mL/min at 37 °C and have been corrected for any binding by warfarin to the support in the absence of entrapped HSA. The protein content of 
each support was calculated in the same manner as described in Table 1.
b
The total volume of the HSA/glycogen solution (or HSA/buffer mixture) that was used in the listed slurry method was 0.40 mL to make it 
equivalent to the HSA/glycogen solution volume that was used for on-column entrapment.
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Table 3.











Slurry method lOmg/mLCon A 13.4 (±1.2) 17.6 (±2.3) 0.33 (±0.04)
On-column method 1.0 mg/mLCon A 16.0 (±1.2) 21.0 (±2.6) 0.40 (±0.05)
On-column method 10 mg/mLCon A 34.7 (±2.9) 45.6 (±5.7) 0.86 (±0.11)
a
The numbers in parentheses represent a range of ± 1 S.D., as obtained for a set of three injections. The specific retention factors were measured at 
0.5 mL/min and 20 °C and have been corrected for any binding by MUM with the support in the absence of MUM. The protein content of each 
support was calculated from the specific retention factor for MUM by using a molar mass for the monomer of Con A of 26.5 kDa, the measured 
void volume of the column, the known packing density for the support (0.45 g/cm3), and an association equilibrium constant of 4.5 × 105 M−1 for 
MUM with Con A at pH 5.0 and 25 °C [28].
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